Double Vision Isn't Unusual in Parkinson's Disease

Article

Though roughly 14 percent of Parkinson's disease patients seen in routine practice have diplopia, most have not discussed it with their physicians, according to a new study presented at the annual meeting of the World Congress of Neurology, held from September 21-26, 2013, in Vienna.

While roughly 14 percent of Parkinson’s disease patients who are seen in routine practice have diplopia, most have not discussed it with their physicians, according to a new study presented at the annual meeting of the World Congress of Neurology, held from September 21-26, 2013, in Vienna.

For their abstract, Anna Sauerbier and colleagues at King’s College of London reviewed data gathered prospectively from Parkinson’s disease patients seen in two neurology clinics. The patient evaluations were conducted with a self-reported Non-Motor Symptoms Questionnaire (NMSQ) and the Non-Motor Symptoms Scale (NMSS), which draws a distinction between diplopia and blurred vision to ensure that the two conditions don’t get confused with one another.

After questioning 257 consecutive patients with Parkinson’s disease, the investigators found that 14.2 percent of the study population, or 35 patients, reported symptoms of diplopia in interviews and self-report questionnaires. The researchers also found that diplopia was significantly correlated with a variety of other non-motor symptoms of the disease.

Among the 35 patients with diplopia, 23 were rated mild, nine were rated moderate, and four were rated severe. Most patients reported that they had not discussed their double vision during their previous visits.

Visual hallucinations were most closely linked with diplopia. Diplopia was also weakly yet significantly associated with patient age and Hoen and Yahr score.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.